The grades of five pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
This week, Shire PLC Sponsored ADR (SHPG) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Shire, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, Earnings Revisions and Equity, SHPG also gets A’s. The stock price has risen 11.7% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of SHPG stock.
Merck & Co., Inc. (MRK) gets a higher grade this week, advancing from a B last week to an A. Merck is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. For more information, get Portfolio Grader’s complete analysis of MRK stock.
Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Teva Pharmaceutical Industries is engaged in the provision of pharmaceutical services. For more information, get Portfolio Grader’s complete analysis of TEVA stock.
The rating of Watson Pharmaceuticals (WPI) moves up this week, rising from a B to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This week, Hospira, Inc. (HSP) pushes up from a C to a B rating. Hospira is a global pharmaceutical and medication delivery company that develops, manufactures and markets products. For more information, get Portfolio Grader’s complete analysis of HSP stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.